Literature DB >> 12677429

Japanese guidelines for diagnosis and treatment of junctional and dystrophic epidermolysis bullosa.

Katsuto Tamai1, Isao Hashimoto, Katsumi Hanada, Shigaku Ikeda, Sadao Imamura, Hideoki Ogawa.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12677429     DOI： 10.1007/s00403-002-0379-y

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN： 0340-3696            Impact factor:   3.017


× No keyword cloud information.
  5 in total

1.  A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).

Authors:  Clare L Rogers; Matthew Gibson; Johannes S Kern; Linda K Martin; Susan J Robertson; Benjamin S Daniel; John C Su; Oliver G C Murrell; Grant Feng; Dedee F Murrell
Journal:  JAAD Int       Date:  2021-01-21

2.  Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa.

Authors:  Marilina Tampoia; Domenico Bonamonte; Angela Filoni; Lucrezia Garofalo; Maria Grazia Morgese; Luigia Brunetti; Chiara Di Giorgio; Giuseppina Annicchiarico
Journal:  Orphanet J Rare Dis       Date:  2013-09-04       Impact factor: 4.123

3.  The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.

Authors:  S V Jain; A G Harris; J C Su; D Orchard; L J Warren; H McManus; D F Murrell
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-10-03       Impact factor: 6.166

Review 4.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

5.  Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders.

Authors:  Paula Davila-Seijo; Angela Hernández-Martín; Evanina Morcillo-Makow; Raúl de Lucas; Esther Domínguez; Natividad Romero; Eva Monrós; Marta Feito; Luis Carretero; Bea Aranegui; Ignacio García-Doval
Journal:  Orphanet J Rare Dis       Date:  2013-04-22       Impact factor: 4.123
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.